Next Article in Journal
Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment
Previous Article in Journal
3. How Comprehensive Can We Be in the Economic Assessment of Vaccines?
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy

by
Dimitrios Tsourougiannis
Medical Affairs, HEOR, EMEA Astellas Pharma Europe Ltd, Chertsey, UK
J. Mark. Access Health Policy 2017, 5(1), 1340747; https://doi.org/10.1080/20016689.2017.1340747
Submission received: 23 January 2017 / Revised: 1 January 2017 / Accepted: 7 June 2017 / Published: 30 June 2017

Abstract

Background: Cost-containment initiatives are re-shaping the pharmaceutical business environment and affecting market access as well as pricing and reimbursement decisions. Effective price management procedures are too complex to accomplish manually. Prior to February 2013, price management within Astellas Pharma Europe Ltd was done manually using an Excel database. The system was labour intensive, slow to update, and prone to error. An innovative web-based pricing information management system was developed to address the shortcomings of the previous system. Development: A secure web-based system for submitting, reviewing and approving pricing requests was designed to: Track all pricing applications and approval status; update approved pricing information automatically; provide fixed and customizable reports of pricing information; collect pricing and reimbursement rules from each country; validate pricing and reimbursement rules monthly. Several sequential phases of development emphasized planning, time schedules, target dates, budgets and implementation of the entire system. A test system was used to pilot the electronic (e)-pricing system with three affiliates (four users) in February 2013. Outcomes: The web-based system was introduced in March 2013, currently has about 227 active users globally and comprises more than 1000 presentations of 150 products. The overall benefits of switching from a manual to an e-pricing system were immediate and highly visible in terms of efficiency, transparency, reliability and compliance. Conclusions: The e-pricing system has improved the efficiency, reliability, compliance, transparency and ease of access to multinational drug pricing and approval information.
Keywords: pharmaceutical business environment; market access; external reference pricing; e-pricing system pharmaceutical business environment; market access; external reference pricing; e-pricing system

Share and Cite

MDPI and ACS Style

Tsourougiannis, D. Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy. J. Mark. Access Health Policy 2017, 5, 1340747. https://doi.org/10.1080/20016689.2017.1340747

AMA Style

Tsourougiannis D. Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy. Journal of Market Access & Health Policy. 2017; 5(1):1340747. https://doi.org/10.1080/20016689.2017.1340747

Chicago/Turabian Style

Tsourougiannis, Dimitrios. 2017. "Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy" Journal of Market Access & Health Policy 5, no. 1: 1340747. https://doi.org/10.1080/20016689.2017.1340747

APA Style

Tsourougiannis, D. (2017). Drug Pricing and Reimbursement Information Management: Processes and Decision Making in the Global Economy. Journal of Market Access & Health Policy, 5(1), 1340747. https://doi.org/10.1080/20016689.2017.1340747

Article Metrics

Back to TopTop